Sutro Biopharma (FRA:S09) Total Liabilities : €280.9 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Sutro Biopharma Total Liabilities?

Sutro Biopharma's Total Liabilities for the quarter that ended in Mar. 2024 was €280.9 Mil.

Sutro Biopharma's quarterly Total Liabilities declined from Sep. 2023 (€299.27 Mil) to Dec. 2023 (€294.44 Mil) and declined from Dec. 2023 (€294.44 Mil) to Mar. 2024 (€280.95 Mil).

Sutro Biopharma's annual Total Liabilities increased from Dec. 2021 (€78.63 Mil) to Dec. 2022 (€179.26 Mil) and increased from Dec. 2022 (€179.26 Mil) to Dec. 2023 (€294.44 Mil).

Sutro Biopharma Total Liabilities Historical Data

The historical data trend for Sutro Biopharma's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sutro Biopharma Total Liabilities Chart

Sutro Biopharma Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

52.72

51.02

78.63

179.26

294.44

Sutro Biopharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															161.21	286.30	299.27	294.44	280.95

Sutro Biopharma Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Sutro Biopharma's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	85.965	+	(21.232	+	1.554
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	185.686	+	0)
	=	294.4

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	431.665	-	137.228
	=	294.4

Sutro Biopharma's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	73.148	+	(19.685	+	1.559
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	186.556	+	0)
	=	280.9

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	371.13	-	90.182
	=	280.9

Sutro Biopharma Total Liabilities Related Terms

Thank you for viewing the detailed overview of Sutro Biopharma's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Sutro Biopharma (FRA:S09) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sutro Biopharma Inc (FRA:S09) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

STRO:USA S09:Germany

Address

111 Oyster Point Boulevard, South San Francisco, CA, USA, 94080

Website

https://www.sutrobio.com

Sutro Biopharma Inc is clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

Sutro Biopharma (FRA:S09) Headlines

No Headlines